JMP Securities analyst Roy Buchanan raised the firm’s price target on Dynavax to $25 from $24 and keeps an Outperform rating on the shares. Dynavax’s top line results beat consensus estimates, with 73% year-over-year growth in HEPLISAV-B revenues, resulting in increased HEPLISAV-B guidance for 2023, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DVAX:
- Dynavax files automatic mixed securities shelf
- Dynavax raises FY23 HEPLISAV-B net product revenue outlook to $200M-$215M
- Dynavax reports Q2 EPS 3c, consensus (9c)
- Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
- DVAX Earnings this Week: How Will it Perform?
